Endo Tools Reports 1st U.S. Commercial Cases of the Endomina System

Endo Tools Reports 1St U.s. Commercial Cases Of The Endomina System
Endomina System

Endo Tools Therapeutics (ETT), developers of advanced endoscopic medical devices, today announced first U.S. commercial cases of the endomina® system. The system is designed for endoscopic placement of suture(s) and approximation of soft tissue in the gastrointestinal tract. The first endomina procedures were performed by Dr. Chris Thompson and Dr. Pichamol Jirapinyo at Brigham and Women’s Hospital in Boston, MA.

“We are thrilled to be the first hospital in the U.S. to perform gastric procedures using the endomina system. The system offers a minimally invasive option with a large working space to approximate very large plications,” said Dr. Thompson. “I look forward to incorporating endomina into my daily practice, as I found it particularly easy to learn and use due to its unique design.”

The endomina system is comprised of a triangulation platform and suturing units (TAPES). It can be affixed to various tested standard endoscopes, providing a bendable therapeutic channel that can move independently. Physicians will be able to perform suturing like a laparoscopic intervention but through a natural orifice, the mouth. The endomina system is the only technology that can be assembled on the endoscope in the stomach for a greater working space and easy introduction of instruments into the esophagus.

“We are delighted the endomina system is now available to patients and physicians in the U.S. market,” said Alexandre Chau, chief executive officer, Endo Tools Therapeutics. “The successful completion of these first cases in the U.S. demonstrates potential for this technology to improve the lives of patients undergoing gastric surgery.”

The endomina system is CE marked and has received 510k clearance in the U.S. More than 500 procedures have already been performed with the company’s devices globally.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution